LABT · Lakewood-Amedex Biotherapeutics Inc. · Documents

Substantial doubt about the company's ability to continue as a going concern.

“The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued. Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”